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OBJECTIVE: Although volatile anesthetics have been w idely accepted in anesthetic 
management for neurosurgery, they reduce vascular resistance, resulting in increased 
cerebral blood flow and increased intracranial pressure (TCP). In patients with elevated 
ICP who undergo craniotomy, the increase in ICP during surgery from inhaled anes­
thetics can make the surgery more difficult, thereby increasing the risk of ischemic cere­
bral insults. Total intravenous anesthesia (TIVA) using propofol and analgesic drugs 
(remifentanil or fentanyl) and excluding simultaneous administration of any inhaled 
drugs is being used in patients undergoing craniotomy because of its potential to reduce 
ICP and ease access to the operative site.
M ETH O D S: W e reviewed the literature and describe our experience with TIVA, with 
emphasis on hemodynamic stability, effects on ICP, emergence from anesthesia, extu- 
bation times, and return of cognitive function in patients undergoing craniotomy for 
space-occupying lesions.
RESULTS: TIVA with propofol is similar to inhaled anesthetics with regard to hemo­
dynamic stability, emergence times, extubation times, early cognitive function, and 
adverse events. In several prospective, randomized clinical trials, evidence suggests 
that ICP is decreased and cerebral perfusion pressure is increased in patients receiv­
ing TIVA when compared with those receiving volatile anesthetics during elective 
craniotomy procedures.
C O N C L U S IO N : The impact of TIVA on ICP, brain swelling, and access to the opera­
tive site in patients with severely elevated ICP has yet to be evaluated and is the sub­
ject of a future study at our institution.
KEY W O R D S: Anesthesia, Inhalants, Intravenous, Propofol
Neurosurgery 61 IONS Suppl 2 l:ONS369-ONS378, 2007  DOI: 10.1227/01 .NFU.0000280138.21916.DB
J k  nesthesia for neurosurgical patients undergoing 
intracranial procedures should provide hemodynamic 
/  mstability, reduce cerebral metabolism, preserve cerebral 
autoregulation, avoid increases of intracranial pressure, and 
guarantee rapid recovery (36, 61, 69). In the last few years, 
volatile anesthetics (isoflurane, sevoflurane, and desflurane) 
combined with synthetic opioids (remifentanil and fentanyl) 
have been used most frequently for neurosurgical procedures 
because these combinations allow for rapid recovery and 
prompt neurological assessment (36, 61, 63). However, volatile 
anesthetics have been shown to affect cerebral autoregulation 
(38) and intracranial pressure (ICP) (36, 60), which can make 
the surgery more difficult and dangerous, increasing the risk of 
ischemic cerebral insults.
The benefits of total intravenous anesthesia (TIVA), which 
is defined as the combination of an intravenous hypnotic 
agent (e.g., propofol) and a synthetic opioid (e.g., fentanyl or
remifentanil), excluding simultaneous administration of any 
inhaled drugs (7, 8, 50), are well recognized. TIVA with propo- 
fol-remifentanil is similar to inhaled anesthesia in that it has 
a short half-life, and therefore allows rapid recovery from sur­
gery (5, 36). Because TIVA has a comparable influence on sys­
temic hemodynamics to inhaled agents (61), the reduction in 
cerebral blood flow (CBF) with increase in cerebral vascular 
resistance seems to make TIVA the more advantageous anes­
thesia technique for patients with increased ICP (27, 36, 48, 63, 
64). We performed a comprehensive literature review by 
searching PubMed using various combinations of the key­
words "TIVA," "total intravenous anesthesia," "propofol," 
"n eu rosu rgery ," and "cran iotom y ," w ith em phasis on 
prospective trials, to evaluate the differences between TIVA 
and volatile anesthesia with regard to hemodynamic stability, 
maintenance of cerebral perfusion pressure (CPP), control of 
ICP, facilitation of a slack brain for surgical dissection, and
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smooth, rapid emergence for early neurological assessment. 
We conclude with a discussion of our experience with TIVA 
for patients undergoing craniotomy.
History of Intravenous Anesthesia
Total intravenous anesthesia has a long history, beginning 
with the original report by Pierre-Cyprien in 1872 in which he 
described his use of chloral hydrate (44). Subsequently, the 1934 
introduction of thiopentone into clinical practice popularized 
intravenous induction of anesthesia (6). In the 1960s, benzodi­
azepines were introduced; they ultimately proved useful as 
intravenous agents to relieve anxiety without producing the 
same degree of sedation as barbiturates. Concurrently, keta- 
mine was introduced as a complete anesthetic in 1966 without 
the depressant cardiovascular effects previously noted (44). 
Despite these new uses of medications, intravenous anesthesia 
remained underutilized as a mode of complete anesthesia 
because of delayed emergence associated with the use of bar­
biturates or benzodiazepines during long procedures; addi­
tionally, delivery systems were complicated when compared 
with those for easy-to-administer volatile anesthetics (69).
Propofol, which was introduced in 1977 (30, 31, 67), elimi­
nated most of the disadvantages of the other intravenous 
agents. As a consequence, and in particular because of its rapid 
recovery profile, propofol has achieved widespread use. It can 
provide all of the components (hypnosis, amnesia, and surgical 
immobility) of a true anesthetic, and when combined with an 
opioid, it is described as total intravenous anesthesia (TIVA). 
This combination offers excellent and predictable recovery con­
ditions while minimizing postoperative side effects, especially 
nausea and vomiting (18).
Anesthetic Agents and General Effects on Increased 
Intracranial Pressure
The goal of neurosurgical anesthesia is to provide the patient 
with an adequate anesthetic (amnesia/sedation, hemodynamic 
stability, and immobility to surgical stimulation) that provides 
optimal operating conditions (e.g., low CBF, cerebral metabolic 
rate [CMR], ICP, and minimal brain bulk), neurological protec­
tion, and rapid emergence from anesthesia for neurological 
examination. An ideal agent for patients with intracranial 
hypertension would decrease ICP by a proportional reduction 
in both CBF and CMR (69). In general, anesthetic agents sup­
press CMR, although ketamine and N20  are notable excep­
tions (Table 1). Increasing plasma concentrations of anesthetics, 
including barbiturates, isoflurane, sevoflurane, desflurane, and 
propofol, cause progressive suppression of electroencephalo­
gram (EEG) activity and a concomitant reduction in CMR (44, 
55). However, the CMR-CBF relationship is not the same for all 
anesthetics, so the anesthetic-induced changes in CBF and ICP 
are also likely a consequence of direct effects on cerebral vascu­
lar smooth muscle (e.g., vasodilation and alteration of autoreg- 
ulatory function).
Minimum alveolar concentration (MAC) is a unit that de­
scribes the steady-state alveolar end-tidal concentration of 
volatile anesthetic that results in immobility in response to sur-
TABLE 1 . Sp ecific  c ffcc ts  o f sc lcc tiv c  an esthesia  used in neuro­
anesthesia
A ffected  p aram eter 
C erebral b lood flow  C erebral
Drug and intracranial m etab o lic  rate
pressure (referen ce  no.) (re feren ce  no.)
Ketamine Increase (28, 69) Increase (28, 69)
Nitrous oxide Increase (19, 47, 51) Increase (21)
Halothane Increase (1, 42) Decrease (34)
Enflurane Increase (33, 62) Decrease (33, 62)
Isoflurane Increase (1, 15) Decrease (35)
Desflurane Increase i'i'i, 62) Decrease (33, 62)
Sevoflurane Increase (33, 62) Decrease (4)
Thiopental Decrease (69) Decrease (69)
Etomidate Decrease (69) Decrease (69)
Propofol Decrease (52, 66) Decrease (16, 52, 66)
gical incision in 50% of patients. For example, 1.3 to 1.5 MAC 
provides "general anesthesia" to 99% of all adults. Although 
volatile anesthetic agents can provide complete general anes­
thesia, the dose-dependent uncoupling of the CMR-CBF rela­
tionship limits the use of more than 0.5 to 0.8 MAC of volatile 
anesthetic supplemented with the use of short-acting (fentanyl) 
and ultra-short-acting (remifentanil) synthetic opioids. During 
administration of 0.67 MAC of volatile anesthetic, the cerebral 
metabolism is decreased 56 to 74% while the CBF and cerebral 
blood volume are unchanged from that of an unanesthetized 
patient (26). In contrast, at an equal anesthetic depth, propofol 
produces a 50 to 68% decrease in cerebral metabolic rate, a 53 
to 70% decrease in CBF, and a 25% decrease in cerebral blood 
volume (26). Thus, the combination of propofol-remifentanil 
may provide a more satisfactory result for patients with 
intracranial space-occupying lesions, mass-related cerebral 
edema, or intracranial bleeds than the combination of a low- 
dose volatile anesthetic with remifentanil.
Volatile or Inhaled Anesthetics
All volatile anesthetics suppress cerebral metabolism in a 
dose-related manner (33, 62) in addition to having a direct 
effect on vascular smooth muscle that results in vasodilation. 
The net effect is therefore a competition between a reduction in 
CBF caused by CMR suppression and augmentation of CBF as 
a result of direct cerebral vasodilation (44).
Halothane has been demonstrated to produce cerebrova- 
sodilation that in turn is associated with an increase in ICP 
(2, 13, 23). Studies have demonstrated that isoflurane mini­
mized CBF when compared with halothane (10, 62). Because 
it was assumed that the effect on ICP was directly a result of 
effects on CBF, isoflurane became a preferred volatile anes­
thetic for neurosurgical cases based on initial findings that it 
caused lesser changes in CBF (10). This dogma held until 
the first comparative studies on ICP effects of anesthetics
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were reported. In 1987, Scheller et al. (57) examined the ICP 
effects of halothane and isoflurane given to morphine/N20 -  
anesthetized rabbits with preexisting intracranial hyper­
tension. Although isoflurane may have limited the increase 
in CBF as compared with halothane, no ICP differences 
between the groups were noted (57). Today, it is generally 
accepted that the order of vasodilating potency among the 
volatile anesthetics is approximately halothane >  enflurane 
>  desflurane -  isoflurane >  sevoflurane (Table 1) (10).
The addition of N20 ,  which is a potent cerebral vasodilator, 
causes or exacerbates increases in CBF and ICP when given 
alone or in com bination with a volatile agent (3, 9, 25). 
Although no uniform agreement regarding the effect of N2O on 
CMR has been reached, evidence suggests that the vasodilatory 
action of N20  can be clinically significant in neurosurgical 
patients with reduced intracranial compliance (21). In circum­
stances in which ICP is persistently elevated or the surgical 
field is persistently "tight," N20  should be viewed as a poten­
tial contributing factor (Table 1) (44).
Barbiturates
Like other central nervous system depressants, barbiturates 
have potent effects on CMR. Several studies in the 1970s 
demonstrated the effect of barbiturates to be a dose-related 
depression in CMR, which produces progressive slowing of 
the EEG, a reduction in the rate of adenosine triphosphate 
(ATP) consumption, and protection from incomplete cerebral 
ischemia (40, 41). With reduction in CMR comes a parallel 
reduction in cerebral perfusion, which is seen as decreased CBF 
and ICP, but the long duration of action of thiopental has lim­
ited the use of this drug for purposes other than induction or 
when burst suppression is needed (Table 1).
Propofol
Propofol, on the other hand, clears more rapidly than barbi­
turates, yet it is also capable of reducing CBF and ICP (66). In 
patients with normal ICP, propofol has been shown to reduce 
CMR by 36% and ICP by 30% while minimally decreasing CPP 
by 10% (54). Normal cerebral reactivity to carbon dioxide and 
autoregulation are maintained during propofol infusion (22). It 
may also decrease blood pressure (and hence CPP) after bolus 
injections (Table 1). Although the use of propofol as a neuropro­
tectant for cerebral ischemia during certain neurosurgical pro­
cedures has been advocated, this may be limited to mild 
ischemic insults (11, 29). For moderate to severe insults with 
prolonged recovery periods, the neuroprotective effects of 
propofol fail and are not sustained to the same degree as seen 
with the use of barbiturates (29).
Opioids
For many years, opioids were assumed to have no impor­
tant effects on ICP and CBF as long as ventilation was con­
trolled (24). In general, opioids produce modest decreases in 
CMR and ICP, although the changes are influenced by the 
concomitant administration of other agents and anesthetics. 
O pioids decrease CBF when com bined w ith N 20  (63).
Opioids usually have no influence or result in only a small 
increase in CBF (Table 1).
C om parison  o f  Inhaled A nesthesia and TIVA 
on H em od ynam ic Stability and Recovery for 
N eurosurgical Patients
Many anesthetics have been used during intracranial sur­
gery, but it is impossible to determine whether a single agent or 
combination of agents is ideal for all situations. In the past few 
years, the anesthetic regimens of isoflurane with fentanyl, and 
more recently, of sevoflurane with fentanyl, have been the most 
frequently used for neurosurgical procedures because they 
allow for a rapid recovery, prompt neurological assessment 
and are considered acceptable in terms of short-term outcome 
(61, 63). However, because volatile anesthetics have been 
shown to affect cerebral autoregulation whereas propofol anes­
thesia preserves it, the best choice of anesthetics for neurosur­
gical patients remains controversial (60). Experimental and clin­
ical studies of recovery time and cerebral hemodynamics 
including CBF, CMR, and ICP have been conducted during 
administration of isoflurane, sevoflurane, and propofol anes­
thesia. In some studies, an increase in ICP and CBF has been 
found during anesthesia with isoflurane and sevoflurane; how­
ever, in other studies of these agents, CBF and ICP were 
unchanged. In contrast, a dose-related decrease in CBF, CMR, 
and ICP has been found during propofol anesthesia. Only a 
few comparative studies demonstrating the effects on emer­
gence time, hemodynamics, and ICP are available, and these 
are described below.
Van Hemelrijck et al. (65) compared the hemodynamics sta­
bility and length of recovery for thiopental-fentanyl-isoflurane- 
N20  and propofol-alfentanil combinations. They found a 
decrease in blood pressure after induction with thiopental 
sodium was followed by a significant increase in blood pres­
sure and heart rate during intubation. Conversely, blood pres­
sure and heart rate did not change during the propofol-loading 
infusion. However, the administration of alfentanil was fol­
lowed by a similar decrease in blood pressure with a return to 
baseline values during the intubation period. Return of normal 
orientation and concentration was shorter and more pre­
dictable for the patients treated with propofol-alfentanil than 
for those who were administered thiopental sodium (Table 2).
Talke et al. (61) also examined the recovery time from anes­
thesia by comparing anesthesia induced and maintained with 
propofol, anesthesia induced with thiopental and maintained 
with isoflurane, and anesthesia induced with propofol and 
maintained with isoflurane until the dura mater was closed 
and then reverted to propofol (during approximately the last 
10 minutes of surgery). Background anesthesia using N20  and 
fentanyl was carried out among all groups. These authors 
found all three approaches provided comparable heart rate and 
blood pressure readings throughout the procedures. Addition­
ally, no significant differences in recovery time among the three 
groups were observed, although patients in the propofol group 
tended to have slower recoveries than those in the isoflurane 
and isoflurane-propofol groups (Table 2).
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TABLE 2 . Com parative trials o f to tal intravenous anesthesia in neurosurgerya'  b
Series





H em odynam ics Intracranial pressure or brain sw elling







Propofoi-alfentanil vs. thiopental, isoflurane, 
fentanyl, and N?0: open-label, randomized 
trial to evaluate blood pressure at time of 
intubation and emergence from anesthesia in 
patients undergoing brain tumor removal
40 Decrease in blood pressure after 
induction followed by increase 
in blood pressure and heart rate 
in thiopental group; no changes 
seen with propofol induction
Not available Return of normal orientation and 
concentration was faster and more 
predictable for the propofol- 





Propofol vs. isoflurane vs. isoflurane followec 
by propofol: prospective randomized trial 
evaluating emergence time and early cogni­
tive function in patients undergoing elective 
surgery for supra tentorial mass lesions
60 No difference in intraoperative 
hemodynamic stability
Not available No difference in emergence 






Propofol-fentanyl vs. isofiurane-fentanyl: 
prospective randomized trial to evaluate 
hemodynamic stability and time to recovery 
of consciousness in patients scheduled for 
intracranial surgery who scored over 13 on 
the Glasgow Coma Scale
58 Propofol group had decreased 
hypertension in response to 
intubation
Not available No difference in emergence 
times or early cognitive function, 
but a significantly shorter period 
to extubation for the isoflurane 






Sevofiurane-fentanyl vs. propofol- 
remifentanil: prospective randomized trial 
evaluating emergence time and early 
cognitive function in patients undergoing 
elective supra tentorial craniotomy
120 Significantly more hypotension 
and hypertension in propofol 
patients
No significant difference in 
brain swelling, which was 
present in 7 patients with 
sevoflurane and 5 with 
propofol
No difference in emergence 






Propofoi-remifentanii (target controlled 
infusion and manually administered) vs. 
sevofiurane-methohexitone: prospective 
single-blind study to compare hemody­
namics, recovery time, and side effects in 
patients undergoing stereotactic biopsy of 
brain tumor
51 Target control led infusion of 
total intravenous anesthesia 
required less hemodynamic 
intervention than manual 
administration of total intra­
venous anesthesia or admini­
stration of sevoflurane
Not available No significant difference 




Propofol-fentanyl vs. isoflurane-N^O: 
prospective randomized trial to evaluate 
clinical differences in patients undergoing 
elective removal of supratentorial mass 
lesion
121 No significant differences No clinically important differ­
ences in mean intracranial pres­
sure measured via the first burr 
hole, but 9 patients in the iso- 
flurane-N^O group had intra­
cranial pressure that measured 
24 mmHg or higher, compared 
with 2 patients in the other group
No difference in emergence 







Propofol vs. isoflurane vs. sevoflurane (all 
with fentanyl): prospective randomized trial 
for evaluation of intracranial pressure for 
patients undergoing elective craniotomy for 
supratentorial tumors
117 Not available After bone removal, decreased 
median intracranial pressure, in­
creased median cerebral perfusion 
pressure, and decreased swelling 
after dural opening for propofol 
compared to others; no difference 
in PCO?, temperature, tumor size, 






Propofol-fentanyl vs. isofiurane-fentanyl: 
prospective randomized trial evaluating 
intracranial pressure, cerebral perfusion 
pressure, and cerebral swelling in children 
undergoing surgery for supra- and 
infra tentorial mass lesions
48 Not available No significant difference in mean 
intracranial pressure measured 
after bone removal, but cerebral 
perfusion pressure and mean 
arterial pressure decreased in the 
isoflurane group; no difference in 
PCO2, temperature, tumor size, 






Propofoi-rem ifentan i I: prospective 
evaluation of postoperative complications 
for total intravenous anesthesia for elective 
neurosurgeries
145 Not available Not available Rapid return of consciousness 
and extubation without any 
respiratory complications
a pco2, partial pressure of carbon dioxide. 
b Trials are listed in the order in which they appear in text.
''Actual intracranial pressure monitoring was performed. 
dIncluded some patients who underwent neurosurgeries other than craniotomies.
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Fabregas et al. (12) analyzed hemodynamic stability and 
recovery time without the complicating effects of N20  for 
patients who underwent resection of supratentorial masses. 
Patients in both treatment groups were induced with thiopen­
tal and given fentanyl for analgesia. Treatment groups were 
divided according to maintenance anesthesia using either 
propofol or isoflurane. The authors found that systolic and 
mean arterial pressures after induction decreased significantly 
in both groups compared with baseline values. In congruence 
with previously cited studies, emergence time and time to 
extubation were shorter for the patients administered isoflu­
rane (Table 2).
Magni et al. (36) compared sevoflurane-fentanyl against 
propofol-remifentanil in patients undergoing craniotomy for 
supratentorial expanding lesions. The primary goal of this 
study was a comparison of early postoperative recovery and 
cognitive function between the two groups. In addition, 
hemodynamic events were analyzed and compared. The 
investigators found that mean recovery times and extubation 
times were similar between the two groups. The incidence of 
hypotension was greater in the propofol-remifentanil group, 
which is consistent with results published by Ozkose et al. 
(46). Heart rate and mean arterial blood pressure both 
decreased significantly after induction and during mainte­
nance of anesthesia in the propofol group. In addition, no 
difference in early cognitive function during recovery of anes­
thesia was observed. The authors did find an excess of post­
operative hypertensive episodes during recovery and in the 
postoperative period in those patients treated with propofol, 
which was consistent with the results from a previous study 
by Guy et al. (17).
Weninger et al. (70) analyzed whether the addition of a 
target-controlled infusion (or pharmokinetic model-driven, 
computer-controlled pump) system, which is purported to 
administer a smooth and controlled dosage of propofol anes­
thesia, had any effect on hemodynamics and the postoperative 
recovery period compared with either propofol administered 
by a manual technique or methohexitone-sevoflurane. In this 
study, remifentanil was used as a background analgesic compo­
nent for all groups. The hemodynamic effects were found to be 
similar between all groups. All treatments decreased heart rate, 
systolic blood pressure, and diastolic blood pressure, although 
the need for intervention was slightly greater in the sevoflurane 
and manual propofol groups than in the target-controlled infu­
sion propofol group (Table 2).
Wong et al. (71) analyzed postoperative hemodynamic and 
adverse effects associated with TIVA using propofol and 
remifentanil. They reviewed five different types of elective neu­
rosurgical procedures (supratentorial craniotomy, posterior 
fossa craniotomy, intracranial vascular procedures, transsphe­
noidal hypophysectomy, and extracranial procedures). These 
investigators found a rapid return of consciousness and a low 
incidence of respiratory complications. In addition, they found 
that shivering, postoperative nausea and/or vomiting, and 
postoperative hypertension occurred in a significant percentage 
of all patients analyzed, with the overall most adverse effects
identified in patients who underwent posterior fossa surgery or 
intracranial vascular surgery. The overall rate of these side 
effects was significantly related to the anesthetic time.
C om parison  o f  the Effects o f  Inhaled Anesthesia and 
Total Intravenous A nesthesia on Intracranial Pressure
With a focus on the effects of ICP, Todd et al. (63) performed 
a prospective comparative trial of three anesthetics based on 
their widely differing cerebrovascular effects. One group of 
patients received isoflurane-N20  (no intravenous drugs other 
than thiopental for induction), the second group received a 
pure intravenous anesthetic with propofol and fentanyl, and 
the third group received a fentanyl-N20-isoflurane combina­
tion. After the end-tidal carbon dioxide was adjusted to 
30 mmHg, a burr hole was drilled into the cranium, an ICP 
transducer was placed into the epidural space, and readings 
were measured for 1 to 3 minutes. They showed no statistically 
significant intergroup differences for ICP measurements, even 
though more patients in the isoflurane-N20  group had ICP that 
was higher (by 24 mmHg or more) than in the other two 
groups. In addition, the authors found that the fentanyl-N20  
group had the most rapid emergence time but also had a higher 
frequency of vomiting during this postoperative period. No 
differences in postoperative deficits, total hospital stay, or costs 
were appreciated (Table 2).
Petersen et al. (48) investigated possible differences in sub­
dural ICP in patients treated with either propofol-fentanyl, 
isoflurane-fentanyl, or sevoflurane-fentanyl anesthesia. In this 
study, subdural ICP was measured after removal of the bone 
flap in patients undergoing elective craniotomy for cerebral 
supratentorial tumors. ICP alone was found to be significantly 
lower and CPP was found to be significantly higher in the 
propofol group than in the isoflurane and sevoflurane groups. 
Additionally, the arteriovenous difference of oxygen content was 
determined using a jugular-dwelling catheter and was found to 
be higher for the propofol group than for the isoflurane and 
sevoflurane groups. Through extrapolation of this data, cerebral 
blood volume and the vasodilatory effects of propofol were con­
cluded to be less than those of either isoflurane or sevoflurane. 
In a follow-up article, Petersen et al. (49) showed that hyperven­
tilation decreased ICP more in patients treated with isoflurane 
and sevoflurane than in patients treated with propofol. They 
surmised that carbon dioxide reactivity is maintained during 
administration of volatile agents but not with propofol. Their 
findings opposed the results of a previous experiment that 
showed carbon dioxide to be directly related to CPP (20).
Stilling et al. (58) examined the effects of TIVA on ICP, CPP, 
and cerebral swelling in children undergoing posterior cran­
iotomy, in which the patient is placed in the prone position. Two 
forms of anesthesia were compared: isoflurane-N20-fentanyl 
and propofol-fentanyl. The authors found no significant differ­
ence in ICP when patients receiving isoflurane and propofol 
were compared; however, mean arterial pressure and CPP were 
found to be significantly lower in the isoflurane group. 
Furthermore, the tension on the dura mater and the degree of 
cerebral swelling were comparable between the two groups.
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Utah Experience with Total Intravenous Anesthesia  
in Patients with Elevated Intracranial Pressure
In cranial base and neurovascular operations at the Univer­
sity of Utah, we have moved toward using TIVA (e.g., propofol- 
remifentanil) to minimize the brain bulk while providing an 
environment that is conducive to intraoperative neurophysio- 
logical monitoring. Using an eight-channel EEG (Cadwell 
Cascade; Cadwell Laboratories, Kennewick, WA) in a monopo­
lar montage (F3, F4, C3, C4, P3,P4, T5, and T6, referred to as 
CZ) along with an esophageal-placed temperature probe (Mon- 
a-Therm; Mallinckrodt, St. Louis, MO), the depth of anesthesia 
along with cooling and/or warming of the patient are adjusted 
to optimize neuroprotection.
In most cases, a bolus injection of propofol (1-2 mg/kg) in 
combination with a remifentanil infusion (0.1-0.5 (Jg/kg/min) 
is used for induction of anesthesia. This is followed by a short 
period during which an infusion of remifentanil (0.05-0.15 
(jg/kg/min) is combined with a low dose of volatile anes­
thetic (0.5-0.8 MAC desflurane or isoflurane) along with 
hyperventilation to an arterial carbon dioxide tension of 
28-32 mmHg while arterial and venous cannulae are placed 
and the patient is positioned. Soon after the skin incision is 
made, the volatile anesthetic is discontinued, and a propofol 
infusion (100-150 (Jg/kg/min) is added to a lower dose of 
remifentanil (0.05-0.1 (Jg/kg/min). With the concomitant 
administration of 50 g of mannitol and 20 mg of dexametha- 
sone, most patients have a brain that is relaxed and amenable 
to dural opening and deep dissection with minimal retractor 
pressure. In those situations in which the brain is still full (e.g., 
subarachnoid hemorrhage, posterior fossa or middle fossa cra­
nial base mass), the anesthetic is deepened by increasing the 
propofol infusion to a dose that produces a mild amount of 
EEG burst suppression (150-225 (Jg/kg/min) while decreasing 
the remifentanil infusion (<0.1 (Jg/kg/min).
A few patients develop hypotension as a result of these 
higher propofol infusion rates (59). In these patients, an intra­
venous fluid bolus (5-7 ml/kg colloid) is administered to 
ensure euvolemia, and if this is unsuccessful in normalizing the 
blood pressure, a low-dose phenylephrine infusion is adminis­
tered to maintain adequate cerebral perfusion and prevent 
hypotension-induced reflexive cerebral arterial dilation. If cere­
brospinal fluid can be removed to slacken the brain, the high- 
dose propofol infusions are decreased to normal maintenance 
levels (100-150 (Jg/kg/min). On the other hand, in those 
patients in whom focal neurological injury is a concern, the 
mild amount of EEG burst suppression is continued until the 
surgical resection of the mass or the clip ligation of the 
aneurysm is completed.
To facilitate rapid emergence from anesthesia, as the dural 
closure is begun, the propofol infusion is often discontinued 
and a low dose of volatile anesthetic (0.5 MAC desflurane or 
isoflurane) is added to the remifentanil infusion (0.1-0.15 
(Jg/kg/min). In the rare situation in which the brain is still 
full before dural closure and despite drainage of cerebro­
spinal fluid, the propofol infusion is continued at a lower
infusion rate (80-100 (Jg/kg/min). In either case, the de­
creased infusion rate of propofol allows for more rapid clear­
ance of propofol to subhypnotic concentrations. Upon 
removal of the Mayfield frame, the hypnotic agent (propofol 
or volatile anesthetic) and the remifentanil are both discon­
tinued. In most situations, the patient emerges from anesthe­
sia in less than 10 minutes.
We have found a substantial improvement in operating con­
ditions in our patients with cranial base masses and intracranial 
hemorrhages, and therefore we have recently incorporated a 
similar technique with three other patient populations. Because 
of the lack of age-related cerebral atrophy, young patients 
(younger than 50 years) undergoing craniotomy for the place­
ment of subdural grid electrodes for planning resection of med­
ically refractory epileptic lesions seem to benefit from the 
switch to a TIVA from a traditional anesthetic. During posterior 
fossa craniotomies for the treatment of trigeminal neuralgia or 
cranial base tumor resection (vestibular schwannoma, menin­
gioma), the improved brain relaxation may limit the retractor- 
related injury of normal brain. Finally, in patients with trau­
matic brain injury or intracerebral hemorrhage, TIVA may 
provide the optimal cerebral hemodynamic state for the injured 
brain by providing enhanced brain relaxation and preserving 
cerebral autoregulation to all the physiological determinants of 
CBF. The pharmacodynamics of propofol are akin to those of 
phenobarbital, whereas the pharmacokinetic profiles of propo­
fol and remifentanil provide a significantly more rapid emer­
gence and more hemodynamic stability than observed with 
phenobarbital comas.
We have observed improved brain relaxation with TIVA rel­
ative to that achieved with a balanced volatile-opioid anes­
thetic. This may be because we have used TIVA for cranial base 
mass lesions and vascular lesions, whereas most trials compar­
ing anesthetics have been limited to the more common supra- 
tentorial tumors. Furthermore, trials that compare brain relax­
ation betw een anesthetic techniques generally include 
heterogeneous groups of patients with a variety of lesions. 
These patients are assigned to receive a single anesthetic and 
the resultant cerebral hemodynamic parameters are compared 
between groups. Because each of the groups contains a variety 
of lesion types, lesions with a wide range of cerebral edema, 
and lesions in a vast number of different locations (even if lim­
ited to supratentorial lesions), the variability in the baseline 
cerebral hemodynamic parameters makes these studies under­
powered to determine whether a patient with a given lesion 
will have a small or large change in cerebral hemodynamics. To 
rigorously determine whether TIVA quantitatively or qualita­
tively improves cerebral hemodynamics, a cross-over study to 
determine those patient characteristics that predict an improve­
ment with TIVA must be performed.
Potential Limitations o f  Total Intravenous Anesthesia
Our technique has several potential limitations. First, for 
anesthesiologists who are unfamiliar with the use of propofol- 
remifentanil anesthetics, there is a potential for either delayed 
emergence because of accumulation of propofol or intra­
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operative awareness as a result of inadequate propofol 
plasma concentrations. Using a quantitative processed EEG 
(e.g., Bispectral Index, Auditory Evoked Potential Index, 
Specific Entropy, or Patient State Index) as a target for titra­
tion of the propofol infusion may limit the occurrences of 
excessive (14) or inadequate (45) propofol administration. 
Another potential problem with the use of a propofol infu­
sion is the unpredictable development of propofol-related 
infusion syndrome (32). Characterized by the development of 
lactic acidosis, rhabdomyolysis, renal failure, and possibly 
cardiac failure, this potentially devastating syndrome, never­
theless, has no accurate predictors.
Another potential complication of TIVA is the potential for a 
large decrease in cerebral blood volume. This becomes signifi­
cant during stereotactic-guided craniotomies, where brain shift 
may ensue. This problem may be easily overcome with the 
availability of intraoperative imaging. Additionally a large 
decrease in cerebral blood volume may worsen epidural bleeds; 
however, the average decrease of the cerebral blood volume 
with a typical balanced propofol-remifentanil anesthetic is only 
25% (26).
Propofol has been shown to have strong anticonvulsant 
properties and is now widely used in controlling refractory 
status epilepticus (53). Notwithstanding this, TIVA (propofol) 
has also been shown to induce seizure activity when used in 
the context of short-term anesthesia (37, 39, 56, 68).
Finally despite the advantages of TIVA, there is a substantial 
cost differential for TIVA when it is compared with inhaled 
anesthesia. However, the pharmacoeconomic advantages of a 
drug are certainly not limited to minimizing the drug acquisi­
tion costs (43). Perioperative drug costs also depend on the 
need to use potentially expensive antiemetic agents to counter­
act the proemetic side effects of many anesthetics as well as on 
the ability to provide a predictable and fast awakening that 
facilitates neurological testing and minimizes the need for 
unplanned (and costly) radiological evaluation.
CONCLUSIONS
We have reviewed the literature to determine whether 
TIVA offers satisfactory hem odynam ic stability, avoids 
increases of ICP, and ensures rapid recovery with emergence 
and extubation times and rapid return of cognitive function 
in patients undergoing craniotom y for space-occupying 
lesions. Overall, TIVA is similar to volatile anesthetics with 
regard to hemodynamic stability emergence times, extuba­
tion times, early cognitive function, and adverse events. In 
several prospective, randomized clinical trials, evidence sug­
gested that ICP is decreased and CPP is increased in patients 
receiving TIVA relative to those receiving volatile anesthetics 
in elective craniotomy procedures. Our institutional experi­
ence with TIVA in these patients has shown a subjective 
improvement in brain relaxation and surgical access to the 
operative site. The impact of TIVA on ICP, brain swelling, 
and access to the operative site in a study group with severely 
elevated ICP has yet to be evaluated.
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COMMENTS
Cole et al. review the effects of total intravenous anesthesia (TIVA) with propofol and opioids on physiological parameters such as 
cerebral blood flow (CBF), cerebral perfusion pressure, cerebral meta­
bolic rate, intracranial pressure (TCP), and brain relaxation as noted by 
the neurosurgeon. The findings are com pared with the effects of 
volatile anesthetic agents. This is a well-written article. The authors 
make a case for the use of TIVA when brain relaxation is needed, as 
well as present the disadvantages and complications of TIVA. This arti­
cle will make many neurosurgeons think about a greater use of TIVA 
in their practice.
R o b e rt G . G ro ssm an
Houston, Texas
This interesting review article describes m anagement of the patient undergoing intracranial surgery with TIVA. In the past few years, a considerable number of studies have been performed to compare 
TIVA and administration of inhaled anesthetics to patients undergoing 
craniotomy.
There are certain implications in this review article with which we 
strongly agree. Although TIVA is similar to volatile anesthetics with 
regard to hem odynam ic stability (aw akening from anesthesia and 
adverse events), multiple clinical studies suggest that TIVA is a better 
alternative when it comes to a decrease in TCP and an increase in cere­
bral perfusion pressure in elective craniotomy procedures. The authors 
have observed improvem ents in operating conditions in their own 
patients by switching to TIVA; patients have shown improvement in 
cerebral hem odynam ic state, enhancem ent of brain relaxation, and 
preservation of cerebral autoregulation. At our institution, we also see 
this new trend in moving toward TIVA during craniotomies. Patients 
tolerate intravenous anesthetics without acquiring nausea and vomit­
ing  p o stop erativ e ly , and evoked  p o ten tia l m on itorin g  has also  
improved secondary to TIVA.
It is im portant to know that TIVA has potential lim itations. As 
described in the article, TIVA administration has the potential to induce 
a decrease in cerebral blood volume. Its use also creates a small possi­
bility of developm ent of propofol-related infusion syndrome. Cost- 
related concerns are mentioned as a controversial issue. As the authors 
said, "the pharmacoeconomic advantages of a drug are certainly not
limited to minimizing the drug acquisition costs." Other factors include 
the potential decrease in use of anti-emetic agents secondary to coun­
teracting the pro-emetic properties of inhaled anesthetics, and the fast 
awakening that the patient experiences when TIVA is used.
E u g en ia  A yrian 
V la d im ir  Z elm an
Neuroanesthesiologists
I,os Angeles, California
In this article, Cole et al. try to respond to the question of which kind of anesthetic is the best choice when a patient's TCP is increased.
Scheller et al. (6) found no TCP differences between isoflurane and 
halothane administration with cryogenic brain injury in rabbits when 
TCP was increased to approxim ately 20 mmHg. In contrast, Fitch and 
M cD ow all (1) exam ined the effects of halothane on TCP using an 
intracranial expanded balloon. In their study, as ICP increased, so 
did the negative effects of halothane. On the other hand, Reinstrup 
et al. (5) identified differences in halothane and isoflurane distribution 
in human cerebrospinal fluid. Therefore, we think that the cerebral 
lesion size, the degree of lost compliance, and the localization of the 
lesion within the brain should be considered to compare halothane 
and isoflurane.
Guy e ta l. (2) found that when patients received remifentanil, they 
required analgesic administration earlier than patients who received 
fentanyl. Magni et al. (4) and Wong et al. (7) noticed that arterial hyper­
tension was present postoperatively with use of TIVA. We try to treat 
postoperative hypertension w hile avoiding a lack of analgesia by 
administering small doses of fentanyl before the patient wakes up.
Although the neuroprotective effect of propofol is not identical to 
that of barbiturates. (3), the authors of this article, decided to deepen 
the anesthesia using propofol at electroencephalograph burst suppres­
sion. They believed that TIVA would provide better brain relaxation 
over the volatile agents. We agree with this, considering that TIVA is 
superior to volatile anesthetic agents in providing a slack brain, which 
translates to easier handling of the brain by the neurosurgeon, with 
only minor ischemia. The Utah experience with administering TIVA to 
patients with elevated ICP brings a "little light at the end of the tunnel" 
with respect to the controversies surrounding anesthetic choice for 
patients with increased ICP. Although there are limitations to using 
TIVA, they are manageable; otherwise, the authors are thinking aca­
demically when they say that at severely elevated ICP, some studies 
have to be evaluated.
N elson  M izu m o to
Neuroanesthesiologist
E v an d ro  P. d e  O liv e ira
Sao Paulo, Brazil
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Cole et al. offer a review of the literature and description of their experience w ith TIVA in their departm ent at the U niversity of 
Utah. This is an interesting review, although the benefits of propofol- 
based anesthesia for craniotomy have been recognized for more than 20 
years, and propofol-maintained anesthesia has been w idely used for 
craniotom y in the United Kingdom, Europe, and Australia during that 
time. In these countries, computer-controlled infusion devices that tar­
get constant concentrations of propofol (i.e., Diprifusor; AstraZeneca 
Pharmaceuticals) have been available for more than 10 years, whereas 
these devices were not available in the United States. Enthusiasm for 
TIVA in Australia has also increased since the introduction of the ultra­
short acting opioid remifentanil. In our experience, a combination of 
propofol and remifentanil provides excellent operating conditions with 
a rapid and smooth recovery from anesthesia, w ithout the need for 
volatile anesthetics that m ay increase the risk of nausea and vomiting. 
It is of note that the authors' recommendation is not entirely "total 
intravenous anesthesia," as they recommend the use of volatile anes­
th e tic s  a fte r  in d u c tio n  and  tow ard  the end  o f the p ro ced u re . 
Nevertheless, the authors provide an interesting review of the use of 





The authors review the literature concerning the use of TIVA in patients undergoing craniotom y for neurosurgical problems. Their 
research is aimed to compare the m ost significant parameters related to 
anesthesia (among them ICP, CBF and its autoregulation, metabolism, 
tim e to awakening, and hem odynam ic stability) in patients treated 
w ith TIVA and in patients treated w ith volatile anesthetics. According 
to the authors, TIVA seems to positively m odify both ICP and CBF
with no significant effects on the other parameters. They seem to be ori­
ented toward a superiority of TIVA to other anesthetics.
This conclusion is not shared by m ost neuroanesthesiologists, and 
there are several reports in the literature, some of which are quoted also 
by the authors [1], concluding that there is no evidence of the superi­
ority of one type of anesthetic over another (see, in addition, the recent 
work of Sneyd et al. [2]). Moreover, the personal experience quoted by 
the authors is reported only as a general feeling, not as proven evidence 
founded on num bers; therefore, there is no m eans of substantiating 
this opinion. This is particularly important because the authors do not 
really use "total intravenous anesthesia." In fact, they report that they 
use volatile anesthetics as well, for some patients and in some moments 
of anesthesia (not better defined).
I think that this article is an excellent starting point for a prospective 
study on patients undergoing craniotomies w ith different anesthesia. 
Certainly there will be the necessity to measure ICP, CBF, and other 
metabolic parameters, as well as the clinical results in terms of morbid­
ity and length of hospital stay. This will be particularly interesting as it 
pertains to patients w ith increased ICP.
Alessandro Ducati
Turin, Italy
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This article is a w orthy recipe for a very good intravenous anes­thetic; however, it lacks sufficient evidence to support its advan­tages compared w ith proven techniques. We agree that TIVA will lower 
the cerebral m etabolic rate and thus im prove the operative field. 
However, it does not improve cerebral protection. A rapidly emerging 
neurosurgical patient is a worthy goal, but it should not be a blind goal. 
We believe that the m ost appropriate anesthetic is the one that is tai­
lored to each patient. This article seems to advocate the overall superi­
ority of TIVA. H ie technique is useful, but it is only one of m any anes­
thetics available for neurosurgical patients.
Steve Shedd
Neuroa nes thes iologis t
Robert F. Spetzler
Phoenix, Arizona
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